CAR-T cell therapy for triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new treatment using your own immune cells, modified to target a protein called B7-H3 on triple-negative breast cancer cells. It may help if other treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have triple-negative breast cancer (ER-, PR-, HER2-negative).
- You must be well enough to carry out daily activities (Karnofsky score above 60%).
- You must not have cancer that has spread to the brain requiring whole-brain radiation.
- You must have tumors that can be measured or evaluated on scans (RECIST 1.1).
- You must be willing to sign a consent form and release your health information.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are modified to target a protein called B7-H3 found on pancreatic cancer cells. The goal is to see if this therapy can help shrink or control the cancer.
This trial tests a new treatment using your own immune cells (CAR-T cells) to target a protein called CSPG4 found on head and neck cancer cells. It is for people whose cancer has come back or not responded to other treatments.
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets specific proteins on breast cancer cells. It's for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments or can't take them.
This trial tests a new type of immune cell therapy (CAR T cells) that targets two markers on cancer cells: TRAIL-R2 and HER2. It is for people with advanced or recurrent HER2-positive breast cancer that has not been stopped by standard treatment.
This trial tests a new treatment called CAR-T cells that target a protein called B7H3 found on cancer cells. It is for people with a specific type of ovarian, peritoneal, or fallopian tube cancer that has not responded well to platinum chemotherapy or has come back quickly.
This early-phase trial tests CAR-T cells designed to find and attack tumors that show EGFR or B7H3 markers. It may help people with advanced lung cancer or triple-negative breast cancer after standard treatments.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.